Skip to main content
Article thumbnail
Location of Repository

Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy

By Pascale Nicaise Roland, Sabine Grootenboer Mignot, Alessandra Bruns, Margarita Hurtado, Elisabeth Palazzo, Gilles Hayem, Philippe Dieudé, Olivier Meyer and Sylvie Chollet Martin
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2005). Autoantibody profiling as early diagnostic prognostic tool for rheumatoid arthritis. Ann Rheum Dis
  2. (1992). Delbanco TL: How useful is the rheumatoid factor? An analysis of sensitivity, specificity and predictive value. Arch Intern Med
  3. Montecucco C: Autoantibody profile in rheumatoid arthritis during
  4. (2004). Prin L: Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis
  5. (1987). revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum
  6. (2004). Second generation anti-cyclic citrullinated peptide (anti-CCP2) Abs can replace other anti-filaggrin Abs and improves RA diagnosis.
  7. (2004). Skogh T: Antibodies against citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity.
  8. (1992). The antiperinuclear factor (APF) and antikeratin Abs (AKA) in rheumatoid arthritis.
  9. (2006). Tohma S: Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
  10. (2000). Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum
  11. (1998). Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.